Utilizing their protein degradation platform, QuEEN, Monte Rosa Therapeutics is developing a portfolio of small molecule precision medicines that target disease-causing proteins for degradation. Their rational approach and use of molecular glue degraders (MGDs) enable the rapid identification of protein targets and potential product candidates. By reshaping the treatment of diseases, particularly cancer, through small molecule protein degraders, Monte Rosa Therapeutics aims to deliver groundbreaking therapies. Founded in 2020 and headquartered in Boston with laboratory facilities in Basel, the company has raised $32.5 million from investors such as Versant Ventures and New Enterprise Associates. The academic co-founders, Prof. Raj Chopra and Prof. Ian Collins from The Institute for Cancer Research, UK, contribute their expertise to the company's mission.